Trescot Andrea M, Glaser Scott E, Hansen Hans, Benyamin Ramsin, Patel Samir, Manchikanti Laxmaiah
University of Florida, Gainesville, FL 32606, USA.
Pain Physician. 2008 Mar;11(2 Suppl):S181-200.
For thousands of years, opioids have been used to treat pain, and they continue to be one of the most commonly prescribed medications for pain. It is estimated that 90% of patients presenting to pain centers and receiving treatment in such facilities are on opioids. Opioids can be considered broad-spectrum analgesics that act at multiple points along the pain pathway. Unfortunately, opioids also have the potential for great harm, with multiple side effects and potential complications, some of which are lethal. They are also uniquely addictive, which can lead to misuse and diversion. We reviewed the relevant English literature and did thorough manual searches of the bibliographies of known primary and review articles. We utilized pain relief as the primary outcome measure. Other outcome measures were functional improvement, improvement of psychological status, improvement in work status, and evidence of addiction. Short-term use and improvement was defined as less than 6 months and long-term relief was defined as 6 months or longer. The 3 systematic reviews evaluating long-term effectiveness of opioids for chronic non-cancer pain provided unclear and weak evidence. The results of this review showed that many patients in the included studies were dissatisfied with adverse events or insufficient pain relief from opioids and withdrew from the studies. For patients able to continue on opioids, evidence was weak suggesting that their pain scores were lower than before therapy and that this relief could be maintained long-term (> 6 months). There was also weak evidence that long-term opioid therapy with morphine and transdermal fentanyl not only decreases pain but also improves functioning. Limited evidence was available for the most commonly used opioids, oxycodone and hydrocodone. Evidence for the ability to drive on chronic opioid therapy was moderate without major side effects or complications. It is concluded that, for long-term opioid therapy of 6 months or longer in managing chronic non-cancer pain, with improvement in function and reduction in pain, there is weak evidence for morphine and transdermal fentanyl. However, there is limited or lack of evidence for all other controlled substances, including the most commonly used drugs, oxycodone and hydrocodone.
数千年来,阿片类药物一直被用于治疗疼痛,并且它们仍然是最常用的疼痛处方药之一。据估计,前往疼痛中心就诊并在这类机构接受治疗的患者中有90%正在使用阿片类药物。阿片类药物可被视为作用于疼痛传导通路多个位点的广谱镇痛药。不幸的是,阿片类药物也有造成巨大危害的可能性,会产生多种副作用和潜在并发症,其中一些是致命的。它们还具有独特的成瘾性,这可能导致药物滥用和转移。我们查阅了相关英文文献,并对已知的原始文章和综述文章的参考文献进行了全面的人工检索。我们将疼痛缓解作为主要结局指标。其他结局指标包括功能改善、心理状态改善、工作状态改善以及成瘾证据。短期使用及改善定义为少于6个月,长期缓解定义为6个月或更长时间。三项评估阿片类药物对慢性非癌性疼痛长期疗效的系统评价提供的证据不明确且薄弱。本综述结果表明,纳入研究中的许多患者对阿片类药物的不良事件或镇痛效果不佳感到不满,并退出了研究。对于能够继续使用阿片类药物的患者,证据薄弱,表明他们的疼痛评分低于治疗前,且这种缓解可长期维持(>6个月)。也有薄弱证据表明,长期使用吗啡和透皮芬太尼进行阿片类药物治疗不仅能减轻疼痛,还能改善功能。对于最常用的阿片类药物羟考酮和氢可酮,可用证据有限。关于慢性阿片类药物治疗期间驾驶能力的证据为中等,且无重大副作用或并发症。结论是,对于慢性非癌性疼痛的6个月或更长时间的长期阿片类药物治疗,在功能改善和疼痛减轻方面,吗啡和透皮芬太尼的证据薄弱。然而,对于所有其他管制物质,包括最常用的药物羟考酮和氢可酮,证据有限或缺乏。
Pain Physician. 2008-3
Ann Pharmacother. 2004-3
J Trauma Acute Care Surg. 2024-11-1